Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
Acute heart failure
Chronic kidney disease
Renal function
SGLT2 inhibitor
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
31
08
2022
received:
14
06
2022
accepted:
01
09
2022
pubmed:
7
9
2022
medline:
29
11
2022
entrez:
6
9
2022
Statut:
ppublish
Résumé
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved clinical outcomes in patients hospitalized for acute heart failure. In patients with chronic heart failure, SGLT2 inhibitors cause an early decline in estimated glomerular filtration rate (eGFR) followed by a slower eGFR decline over time than placebo. However, the effects of SGLT2 inhibitors on renal function during a hospital admission for acute heart failure remain largely unknown. Between 1 and 5 days after a hospitalization for acute heart failure, 530 patients with an eGFR >20 ml/min/1.73 m In patients hospitalized for acute heart failure, empagliflozin caused an early modest decline in renal function which was no longer evident after 90 days. Acute renal events were similar in both groups. The clinical benefit of empagliflozin was consistent regardless of baseline renal function.
Identifiants
pubmed: 36066557
doi: 10.1002/ejhf.2681
pmc: PMC9828037
doi:
Substances chimiques
empagliflozin
HDC1R2M35U
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1844-1852Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Nat Med. 2022 Mar;28(3):568-574
pubmed: 35228754
Eur J Heart Fail. 2021 May;23(5):826-834
pubmed: 33609072
Eur J Heart Fail. 2020 Apr;22(4):713-722
pubmed: 31912605
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704
pubmed: 29937267
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Eur J Heart Fail. 2020 Apr;22(4):584-603
pubmed: 31908120
Eur J Heart Fail. 2022 Feb;24(2):365-374
pubmed: 34786794
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396